Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Researchers and Healthcare Providers
 Research Grants Program
-Medical and Scientific Advisory Council
 Recent Recommendations
 What is MASAC?
 All MASAC Recommendations
 MASAC Members
 Nursing Working Group
 Social Work Working Group
 Physical Therapy Working Group
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Cell Based Coagulation Animation
 Rare Bleeding and Clotting Disorders Resource Room
 The Partners in Bleeding Disorders Education Program
 NHF/Novo Nordisk HANDI Library

 

 

 
MASAC Recommendation #101 - MASAC Recommendation Regarding Reimbursement for Tre
 

MASAC Recommendation #101

MASAC Recommendation Regarding Reimbursement for Treatment of Acquired Hemophilia

The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation on May 24, 2000, and adopted by the NHF Board of Directors on June 10, 2000.

It is well documented that persons with acquired hemophilia may require treatment with the same clotting factor concentrates that are used to treat persons with inherited hemophilia complicated by inhibitors. Failure to provide adequate reimbursement for these coagulation therapies may adversely impact patient care, morbidity, and mortality. Thus, the Medical and Scientific Advisory Council of the National Hemophilia Foundation recommends that reimbursement for clotting factor concentrates for persons with acquired hemophilia be the same as for persons with congenital hemophilia with inhibitors.